BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Takahara N, Isayama H, Nakai Y, Sasaki T, Hamada T, Uchino R, Mizuno S, Miyabayashi K, Kogure H, Yamamoto N. A retrospective study of S-1 and oxaliplatin combination chemotherapy in patients with refractory pancreatic cancer. Cancer Chemother Pharmacol. 2013;72:985-990. [PMID: 23995699 DOI: 10.1007/s00280-013-2278-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Wysocka O, Kulbacka J, Saczko J. Adjuvant, neoadjuvant, and experimental regimens in overcoming pancreatic ductal adenocarcinoma. Prz Gastroenterol 2016;11:155-62. [PMID: 27713776 DOI: 10.5114/pg.2016.61438] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
2 Onesti CE, Romiti A, Roberto M, Falcone R, Marchetti P. Recent advances for the treatment of pancreatic and biliary tract cancer after first-line treatment failure. Expert Rev Anticancer Ther 2015;15:1183-98. [PMID: 26325474 DOI: 10.1586/14737140.2015.1081816] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
3 Kasuga A, Okano N, Naruge D, Kitamura H, Takasu A, Nagashima F, Furuse J. Retrospective analysis of fixed dose rate infusion of gemcitabine and S-1 combination therapy (FGS) as salvage chemotherapy in patients with gemcitabine-refractory advanced pancreatic cancer: inflammation-based prognostic score predicts survival. Cancer Chemother Pharmacol 2015;75:457-64. [DOI: 10.1007/s00280-014-2665-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
4 Takahara N, Isayama H, Nakai Y, Ishigami H, Satoi S, Mizuno S, Kogure H, Matsubara S, Yamamoto N, Yamaguchi H, Tada M, Kitayama J, Watanabe T, Koike K. Intravenous and intraperitoneal paclitaxel with S-1 for treatment of refractory pancreatic cancer with malignant ascites. Invest New Drugs 2016;34:636-42. [PMID: 27339809 DOI: 10.1007/s10637-016-0369-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
5 Takahara N, Isayama H, Nakai Y, Sasaki T, Saito K, Hamada T, Mizuno S, Miyabayashi K, Mohri D, Kogure H, Matsubara S, Yamamoto N, Hirano K, Ijichi H, Tateishi K, Tada M, Koike K. Pancreatic cancer with malignant ascites: clinical features and outcomes. Pancreas 2015;44:380-5. [PMID: 25636085 DOI: 10.1097/MPA.0000000000000290] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
6 Walker EJ, Ko AH. Beyond first-line chemotherapy for advanced pancreatic cancer: An expanding array of therapeutic options? World J Gastroenterol 2014; 20(9): 2224-2236 [PMID: 24605022 DOI: 10.3748/wjg.v20.i9.2224] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 33] [Article Influence: 4.8] [Reference Citation Analysis]
7 Chang JS, Chen LT, Shan YS, Chu PY, Tsai CR, Tsai HJ. The incidence and survival of pancreatic cancer by histology, including rare subtypes: a nation-wide cancer registry-based study from Taiwan. Cancer Med 2018;7:5775-88. [PMID: 30264519 DOI: 10.1002/cam4.1795] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
8 Hamada T, Nakai Y, Isayama H, Yasunaga H, Matsui H, Takahara N, Mizuno S, Kogure H, Matsubara S, Yamamoto N, Tada M, Koike K. Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer. European Journal of Cancer 2016;65:11-20. [DOI: 10.1016/j.ejca.2016.05.016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
9 Chou WC, Chen YY, Hung CY, Chen JS, Lu CH, Chang PH. Evolution of the chemotherapeutic landscape and survival outcome in patients with metastatic pancreatic cancer: a four-institute cohort study in Taiwan, 2010-2016. Cancer Manag Res 2019;11:2119-27. [PMID: 30936744 DOI: 10.2147/CMAR.S196300] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]